Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Smallcap 250 and 0.8 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
KIMS has submitted its Q1 FY26 (quarter ended June 30, 2025) unaudited standalone and consolidated financial results, approved by the Board on August 6, 2025. On a consolidated basis, revenue from operations rose to Rs. 8,716 million from Rs. 6,884 million a year ago, a growth of about 26.6% YoY, helped by expansion across subsidiaries. However, consolidated profit before tax declined to Rs. 1,137 million from Rs. 1,271 million, and net profit fell to Rs. 850 million from Rs. 952 million, reflecting higher operating and finance costs. Standalone revenue grew to Rs. 3,734 million from Rs. 3,274 million, with standalone PAT of Rs. 588 million versus Rs. 607 million. The statutory auditor (S.R. Batliboi & Associates LLP) issued an unmodified review opinion with no qualifications.
Strong top-line growth driven by subsidiary ramp-up is positive, but profitability is under pressure due to rising employee, consumable, and finance costs, which may weigh on near-term sentiment despite clean audit comfort.